Gunnar Olof Olsson

Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt is a non-profit organization based in Stockholm, Sweden. and has subsidiaries in Sweden. The organization's main objective is to raise funds for selected Swedish heart and lung research to help people live longer and healthier lives. The Swedish company works together with individuals and companies to collect and distribute funds for heart and lung research. The organization's vision is to create a world free from heart and lung disease. Kärlkramp, which is a temporary reduction of blood flow in the heart's coronary vessels and the main symptom is a squeezing chest pain, is one of the diseases they focus on.